2017-11-06

Webinar April 6 - Interview with Vironova founder and CEO Mohammed Homman

Vironova will host a webinar “Automated purity and integrity check of gene therapy vectors” on April 6 at 3 pm CET. (Agenda and registration can be found here.)

2017-11-06

MiniTEM™ event in Leiden attracts key players within gene therapy and vaccine industries

A full-day event including live demo of MiniTEM and presentations showing how to go from manual to automated virus particle characterization attracted more than 10 different companies located in Europe. Invited speaker Vesa Turkki, Senior Scientist...

2017-11-06

Vironova is building a state of the art electron microscopy (EM) facility to meet increasing demand

Vironova has established a growing number of global customers in the highly-regulated and quality demanding pharmaceutical industry, who focus on drug/gene delivery and vaccine development. Currently 7 of the 10 largest biopharmaceutical companies...

2017-11-06

Vironova has filed a US provisional patent for analyzing viral vector content using cryoTEM

Vironova has now filed a patent for quantitative analysis of viral vector content using cryoTEM, a method that has already triggered plenty of interest amongst our customers.

2017-11-06

Free webinar April 6: Automated purity and integrity analysis of gene therapy vectors

Time: 3:00pm London, 10:00am New York

2017-11-06

Record turnover for NOW Electronics in its first year as a Vironova-owned company

2016 saw Mikael Wik appointed as new CEO and a record sales performance that beat all previous years, with a turnover of 25,9 MSEK. The two founders and previous leaders since 1985 continue to be active in sales and business development.

2017-11-06

European MiniTEM seminar; “Automated virus particle characterization”, March 30 in Leiden

Everybody with a need to speed up process development or secure final product quality of virus particle based therapeutics should attend this seminar. The event offers an opportunity to learn about Vironova’s solutions for nanoparticle...

2017-11-06

Vironova AB is a partner in a Big Data and Computational Science project that has received 29 M SEK in funding from the Swedish foundation for Strategic Research.

Vironova AB is once again a participant in a cutting-edge research program, this time in a Big Data and Computational Science entitled program “Hierarchical Analysis of Temporal and Spatial Image Data.” Transmission electron microscopy (TEM) images...

2017-11-06

Vironova AB signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS).

In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body.

2017-11-06

Vironova is together with AstraZeneca part of a drug delivery technology Industrial Research Centre which has received 75M SEK from the Swedish foundation for Strategic Research (SSF).

At Vironova we are proud about being part of this new FoRmulaEx centre that has been recognized by SSF to meet the highest international scientific standards. The FoRmulaEx centre will develop methods for efficient and robust delivery of complex,...